NPCE
NeuroPace, Inc.
NasdaqGMUSDEQUITY
DELAYED
Last price
14.03
▲ 0.01 (0.07%)
MARKET · —
Price
Open
13.77
Prev close
14.02
Day high
14.20
Day low
13.87
Volume
115.20K
Market cap
—
P/E (TTM)
—
52W range
8.61 – 19.60
Trailing performance
Returnvs SPY
1W
-5.01%
-3.6%
1M
-4.43%
-8.2%
3M
-13.82%
-16.9%
6M
-2.16%
-13.2%
YTD
-9.13%
-21.4%
1Y
+62.01%
+42.0%
3Y
+218.86%
+144.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
14.52
-3.38% from price
SMA 20
14.31
-1.95% from price
SMA 50
15.33
-8.48% from price
SMA 100
15.72
-10.75% from price
SMA 200
15.39
-8.82% from price
EMA 12
14.39
-2.50% from price
EMA 26
14.68
-4.42% from price
EMA 50
15.07
-6.91% from price
RSI (14)
43.1
Neutral
MACD (12,26,9)
-0.29
Hist 0.04
ATR (14)
0.74
5.30% of price
Realised vol 30D
60.5%
Annualised
Bollinger upper
15.55
20, 2σ
Bollinger lower
13.06
20, 2σ
50 / 200 cross
Death
15.33 vs 15.39
Trend bias
Below 200
-8.82%
Risk profile
Beta vs SPY
1.49
More volatile than market
Correlation to SPY
0.31
Loosely linked
Realised vol 30D
60.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-33.2%
Peak to trough
Max drawdown 5Y
-94.6%
Peak to trough
ATR 14
0.74
5.30% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
NeuroPace Inc (NPCE) (Q2 2026) Earnings Call Highlights: Strong RNS Growth and AI Launch Offset ...
GuruFocus.com · 4d ago
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
Zacks · 5d ago
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
Zacks · 5d ago
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
Zacks · 5d ago
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
Zacks · 10d ago
NeuroPace, Inc. Q2 2026 Earnings Call Summary
Moby · 10d ago
NeuroPace Q2 Earnings Call Highlights
MarketBeat · 11d ago
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.